Safety And Efficacy Of Nivolumab In Older Patients (Pts) With Renal Cell Carcinoma: Results Of A Sub-Group Analysis Of The Getug-Afu 26 Nivoren Multicenter Phase Ii Study.

Loic Mourey,Cécile Dalban,Sylvie Negrier,Christine Chevreau,Gwenaelle Gravis,Constance Thibault,Brigitte Laguerre,Philippe Barthelemy,Delphine Borchiellini,Marine Gross-Goupil,Lionnel Geoffrois,Frederic Rolland,Antoine Thiery-Vuillemin,Florence Joly,Sylvain Ladoire,Florence Tantot,Bernard Escudier,Laurence Albiges

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 1|浏览8

暂无评分

摘要

331Background: NIVOREN GETUG AFU 26 study, is a french multicenter prospective study to evaluate safety and efficacy of Nivolumab (N) in a broad “real world setting” in mRCC after failure of 1 or 2...

查看译文

关键词

renal cell carcinoma,nivolumab,older patients,sub-group,getug-afu

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要